Metagenomi Therapeutics EBITDA Margin 2022-2025 | MGX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Metagenomi Therapeutics (MGX) over the last 10 years. The current EBITDA margin for Metagenomi Therapeutics as of September 30, 2025 is .
| Metagenomi Therapeutics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-09-30 | $0.03B | $-0.09B | -284.38% |
| 2025-06-30 | $0.04B | $-0.09B | -265.71% |
| 2025-03-31 | $0.05B | $-0.09B | -197.83% |
| 2024-12-31 | $0.05B | $-0.09B | -173.58% |
| 2024-09-30 | $0.06B | $-0.09B | -167.27% |
| 2024-06-30 | $0.06B | $-0.09B | -167.27% |
| 2024-03-31 | $0.05B | $-0.09B | -204.35% |
| 2023-12-31 | $0.04B | $-0.08B | -190.91% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.058B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.788B | 12.35 |
| BridgeBio Pharma (BBIO) | United States | $13.114B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.756B | 18.29 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.962B | 24.25 |
| Bausch Health Cos (BHC) | Canada | $2.181B | 1.55 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.345B | 9.69 |
| Taysha Gene Therapies (TSHA) | United States | $1.263B | 0.00 |
| Personalis (PSNL) | United States | $0.715B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.415B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.183B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |